Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha
- PMID: 17316976
- DOI: 10.1016/j.mce.2007.01.012
Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha
Abstract
Calmodulin (CaM) contributes to estrogen receptor alpha (ER)-mediated transcription. In order to study the underlying mechanisms, we synthesized a peptide including the CaM binding site: ERalpha17p (P(295)-T(311)). This peptide inhibited ER-CaM association, unlike two analogs in which two amino acids required for CaM binding were substituted. Exposure of MCF-7 cells to ERalpha17p down regulated ER, stimulated ER-dependent transcription and enhanced the proliferation of ER-positive breast cancer cell lines. Interestingly, ERalpha17p analogs unable to bind to CaM induced similar responses, demonstrating that ERalpha17p-mediated effects are mainly relevant to mechanisms independent of ER-CaM dissociation. The P(295)-T(311) motif is indeed a platform for multiple post-translational modifications not necessarily CaM-dependent. The additional finding that deletion of the P(295)-T(311) sequence in ER produced a constitutive transcriptional activity revealed that this platform motif has autorepressive functions. With regard to cell function, association of CaM to ER would counteract this autorepression, leading thereby to enhanced ER-mediated transactivation.
Similar articles
-
Modulation of estradiol and DNA binding to estrogen receptor upon association with calmodulin.Biochem Biophys Res Commun. 1995 Mar 17;208(2):748-55. doi: 10.1006/bbrc.1995.1401. Biochem Biophys Res Commun. 1995. PMID: 7695632
-
Structural determinants of the BRCA1 : estrogen receptor interaction.Oncogene. 2005 Mar 10;24(11):1831-46. doi: 10.1038/sj.onc.1208190. Oncogene. 2005. PMID: 15674350
-
Estrogen receptor-alpha and -beta regulate the human corticotropin-releasing hormone gene through similar pathways.Brain Res. 2008 Aug 5;1223:1-10. doi: 10.1016/j.brainres.2008.05.043. Epub 2008 May 27. Brain Res. 2008. PMID: 18597742
-
Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells.Mol Cell Endocrinol. 2008 Sep 10;291(1-2):20-6. doi: 10.1016/j.mce.2008.04.011. Epub 2008 Apr 26. Mol Cell Endocrinol. 2008. PMID: 18524472 Review.
-
Calmodulin, and various ways to regulate its activity.Life Sci. 2004 Jan 16;74(9):1065-70. doi: 10.1016/j.lfs.2003.07.026. Life Sci. 2004. PMID: 14687647 Review.
Cited by
-
Interaction of the Anti-Proliferative GPER Inverse Agonist ERα17p with the Breast Cancer Cell Plasma Membrane: From Biophysics to Biology.Cells. 2020 Feb 15;9(2):447. doi: 10.3390/cells9020447. Cells. 2020. PMID: 32075246 Free PMC article.
-
The Antitumor Peptide ERα17p Exerts Anti-Hyperalgesic and Anti-Inflammatory Actions Through GPER in Mice.Front Endocrinol (Lausanne). 2021 Mar 17;12:578250. doi: 10.3389/fendo.2021.578250. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33815268 Free PMC article.
-
Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα-positive breast cancer.Front Oncol. 2025 Jun 26;15:1513225. doi: 10.3389/fonc.2025.1513225. eCollection 2025. Front Oncol. 2025. PMID: 40641933 Free PMC article. Review.
-
Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.Mol Oncol. 2013 Jun;7(3):595-610. doi: 10.1016/j.molonc.2013.02.012. Epub 2013 Feb 20. Mol Oncol. 2013. PMID: 23474223 Free PMC article.
-
The Peptide ERα17p Is a GPER Inverse Agonist that Exerts Antiproliferative Effects in Breast Cancer Cells.Cells. 2019 Jun 14;8(6):590. doi: 10.3390/cells8060590. Cells. 2019. PMID: 31207943 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources